论文部分内容阅读
偏头痛是临床常见病 ,多发病之一 ,发病机理尚不完全清楚。随着对其发病机理的不断深入了解 ,开发出 5- HT1B/ 1D受体激动剂 (即曲坦类药物 )作为偏头痛急性发作的有效治疗药 ,是一个科学性的突破 ,开创了治疗偏头痛的新途径。自 1 991年 2月第一个曲坦类偏头痛治疗药 5- HT1B/ 1D受体激动剂舒马曲坦上市以来 ,曲坦类药物的研究方兴未艾 ,发展前景良好。本文综述了几个上市和将要上市的曲坦类药物的临床疗效、代谢及其副作用等
Migraine is a common clinical disease, frequently-occurring disease, the pathogenesis is not yet fully understood. With the continuous understanding of its pathogenesis, the development of a 5HT1B / 1D receptor agonist (ie, triptan) as an effective therapeutic agent for acute attacks of migraine is a scientific breakthrough that pioneered the treatment of partial New way of headache. Since February 1991, the first triptan migraine drug 5-HT1B / 1D receptor agonist Sumatriptan listing, triptan research in the ascendant, good prospects for development. This article reviews the clinical efficacy, metabolism and side effects of several triptans marketed and to be marketed